Mesa Laboratories Future Growth

Future criteria checks 4/6

Mesa Laboratories is forecast to grow earnings and revenue by 138.5% and 7.2% per annum respectively. EPS is expected to grow by 138.7% per annum. Return on equity is forecast to be 30.9% in 3 years.

Key information

138.5%

Earnings growth rate

138.7%

EPS growth rate

Life Sciences earnings growth	17.1%
Revenue growth rate	7.2%
Future return on equity	30.9%
Analyst coverage	Low
Last updated	06 Jun 2024

Recent future growth updates

Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 08

Recent updates

Is Now An Opportune Moment To Examine Mesa Laboratories, Inc. (NASDAQ:MLAB)?

May 03

Is Mesa Laboratories (NASDAQ:MLAB) Using Too Much Debt?

Mar 15

Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 08

Investor Optimism Abounds Mesa Laboratories, Inc. (NASDAQ:MLAB) But Growth Is Lacking

May 31

A Look At The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Apr 12

Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?

Mar 13

Estimating The Fair Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Dec 20

Mesa Laboratories declares $0.16 dividend

Oct 03

Mesa Laboratories: Softening Bottom Line Fundamentals, Fairly Priced

Sep 09

Are Investors Undervaluing Mesa Laboratories, Inc. (NASDAQ:MLAB) By 41%?

Sep 06

Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?

Aug 08

Mesa Laboratories GAAP EPS of -$0.27 misses by $0.27, revenue of $50.45M misses by $1.72M

Aug 04

Mesa Laboratories declares $0.16 dividend

Jul 07

A Look At The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

May 06

Growth Investors: Industry Analysts Just Upgraded Their Mesa Laboratories, Inc. (NASDAQ:MLAB) Revenue Forecasts By 14%

Apr 09

Earnings and Revenue Growth Forecasts

NasdaqGS:MLAB - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2027	270	19	44	N/A	2
3/31/2026	248	5	39	N/A	3
3/31/2025	234	4	31	N/A	2
3/31/2024	216	-254	N/A	N/A	N/A
12/31/2023	213	1	41	44	N/A
9/30/2023	214	-1	36	40	N/A
6/30/2023	219	2	36	41	N/A
3/31/2023	219	1	23	28	N/A
12/31/2022	222	-1	20	25	N/A
9/30/2022	223	-4	28	33	N/A
6/30/2022	200	-2	23	27	N/A
3/31/2022	184	2	35	39	N/A
12/31/2021	163	8	39	43	N/A
9/30/2021	143	5	36	38	N/A
6/30/2021	139	4	42	44	N/A
3/31/2021	134	3	35	37	N/A
12/31/2020	130	-2	31	32	N/A
9/30/2020	128	-2	31	32	N/A
6/30/2020	121	-2	27	29	N/A
3/31/2020	118	2	25	27	N/A
12/31/2019	110	5	27	28	N/A
9/30/2019	105	10	27	28	N/A
6/30/2019	104	8	24	25	N/A
3/31/2019	103	7	29	31	N/A
12/31/2018	104	10	28	30	N/A
9/30/2018	101	-2	27	29	N/A
6/30/2018	99	0	28	30	N/A
3/31/2018	96	-3	23	26	N/A
12/31/2017	94	-4	N/A	17	N/A
9/30/2017	94	11	N/A	14	N/A
6/30/2017	95	11	N/A	7	N/A
3/31/2017	94	11	N/A	17	N/A
12/31/2016	94	12	N/A	14	N/A
9/30/2016	90	11	N/A	9	N/A
6/30/2016	88	10	N/A	18	N/A
3/31/2016	85	11	N/A	17	N/A
12/31/2015	78	9	N/A	15	N/A
9/30/2015	76	9	N/A	16	N/A
6/30/2015	73	10	N/A	13	N/A
3/31/2015	71	10	N/A	11	N/A
12/31/2014	68	11	N/A	9	N/A
9/30/2014	64	10	N/A	11	N/A
6/30/2014	58	9	N/A	10	N/A
3/31/2014	53	9	N/A	12	N/A
12/31/2013	50	8	N/A	12	N/A
9/30/2013	48	8	N/A	12	N/A
6/30/2013	47	8	N/A	11	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MLAB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).

Earnings vs Market: MLAB is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MLAB is expected to become profitable in the next 3 years.

Revenue vs Market: MLAB's revenue (7.2% per year) is forecast to grow slower than the US market (8.5% per year).

High Growth Revenue: MLAB's revenue (7.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MLAB's Return on Equity is forecast to be high in 3 years time (30.9%)

Mesa Laboratories Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Consensus EPS estimates upgraded to US$0.055 loss

Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Price target decreased by 17% to US$115

Price target decreased by 8.9% to US$139

Consensus EPS estimates increase by 14%

Price target decreased by 11% to US$178

Recent updates

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Mesa Laboratories, Inc. Reports Impairment of Goodwill and Long-Lived Assets for the Fourth Quarter Ended March 31, 2024

Upcoming dividend of US$0.16 per share

Is Now An Opportune Moment To Examine Mesa Laboratories, Inc. (NASDAQ:MLAB)?

Third quarter dividend of US$0.16 announced

Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on June 14, 2024

Mesa Laboratories, Inc. to Report Q4, 2024 Results on May 24, 2024

Is Mesa Laboratories (NASDAQ:MLAB) Using Too Much Debt?

Consensus EPS estimates upgraded to US$0.055 loss

Upcoming dividend of US$0.16 per share

Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

New minor risk - Earnings quality

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Mesa Laboratories, Inc. Appoints Mark Capone to Its Board of Directors

Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on March 15, 2024

Insider notifies of intention to sell stock

Mesa Laboratories, Inc. to Report Q3, 2024 Results on Feb 05, 2024

Is Mesa Laboratories, Inc. (NASDAQ:MLAB) Trading At A 43% Discount?

Upcoming dividend of US$0.16 per share at 0.7% yield

Price target decreased by 17% to US$115

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Mesa Laboratories, Inc. (NasdaqGS:MLAB) entered into a definitive agreement to acquire Beijing GKE Science & Technology Co. LTD for €5 million.

Mesa Laboratories, Inc. (NasdaqGS:MLAB) acquired Sterilization indicators business of GKE-GmbH and SAL GmbH from Gke-GmbH for €80 million.

Price target decreased by 8.9% to US$139

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on December 15, 2023

Is Mesa Laboratories (NASDAQ:MLAB) A Risky Investment?

Mesa Laboratories, Inc. to Report Q2, 2024 Results on Nov 06, 2023

CEO, President & Director notifies of intention to sell stock

Upcoming dividend of US$0.16 per share at 0.5% yield

Estimating The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Mesa Laboratories, Inc., Annual General Meeting, Aug 25, 2023

We Think Mesa Laboratories (NASDAQ:MLAB) Is Taking Some Risk With Its Debt

Now 20% undervalued after recent price drop

Mesa Laboratories, Inc. to Report Q1, 2024 Results on Aug 03, 2023

CEO, President & Director exercised options and sold US$166k worth of stock

Consensus EPS estimates increase by 14%

Now 21% undervalued after recent price drop

Investor Optimism Abounds Mesa Laboratories, Inc. (NASDAQ:MLAB) But Growth Is Lacking

Price target decreased by 11% to US$178

Full year 2023 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of US$0.16 per share at 0.4% yield

Mesa Laboratories, Inc. Announces John B. Schmieder, Member of the Board of Directors, Chair of the Nominating and Governance Committee, and Member of the Audit Committee Decide Not to Stand for Re-Election

A Look At The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

VP, CFO & Chief Accounting Officer notifies of intention to sell stock

Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?

VP, CFO & Chief Accounting Officer notifies of intention to sell stock

Upcoming dividend of US$0.16 per share at 0.4% yield

VP, CFO & Chief Accounting Officer exercised options and sold US$132k worth of stock

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

VP, CFO & Chief Accounting Officer exercised options and sold US$293k worth of stock

Independent Director exercised options and sold US$137k worth of stock

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on March 15, 2023

Estimating The Fair Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Mesa Laboratories, Inc. to Report Q3, 2023 Results on Feb 06, 2023

Upcoming dividend of US$0.16 per share

Now 21% undervalued after recent price drop

Mesa Laboratories, Inc. (NasdaqGS:MLAB) acquired Substantially all of the assets and certain liabilities from Belyntic GmbH.

Mesa Laboratories, Inc. Appoints Tony Tripeny as Member of Audit Committee

Second quarter 2023 earnings released: EPS: US$0.24 (vs US$0.71 in 2Q 2022)

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on December 15, 2022

Mesa Laboratories declares $0.16 dividend

Mesa Laboratories: Softening Bottom Line Fundamentals, Fairly Priced

Are Investors Undervaluing Mesa Laboratories, Inc. (NASDAQ:MLAB) By 41%?

VP, CFO & Chief Accounting Officer exercised options and sold US$143k worth of stock

Upcoming dividend of US$0.16 per share

Independent Director recently sold US$198k worth of stock

VP, CFO & Chief Accounting Officer exercised options and sold US$260k worth of stock